All News

ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.

Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.

Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.

In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.

Jessica Shepherd, MD, MBA, FACOG, joins Missed & Dismissed to discuss why perimenopause is overlooked and how disparities shape who gets care.

Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.

Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.

Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.

Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.

JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.

Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.

Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.

NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.

Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.

JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.

Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.

Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.

Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.

Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.

A systematic review found transdermal nitroglycerin may modestly reduce hot flashes, but evidence remains limited.

The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.

The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.

The Menopause Society's 2026 meeting in San Diego will tackle estrogen avoidance, cancer survivorship, mood, and sleep.

SWHR, ACOG, and WFRC called for sustained funding after a new women’s health executive order.

Real-world fezolinetant (Veozah) sleep data help ob-gyns counsel patients hesitant about hormone therapy, according to Marla Shapiro, CM, MDCM.

Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.

Experts address COVID-19 vaccine myths, safety evidence, and how to frame the benefits of vaccination in pregnancy.

Experts look ahead to new maternal vaccines and how to counsel patients on receiving several in one pregnancy.